Corona Remedies — 360° view

Corona Remedies, a company in the Pharmaceuticals industry, reported revenue of ₹441 crore and net profit of ₹60 crore for the September 2026 quarter.

Corona Remedies (NSE: CORONA) closed at ₹2,263.20 on 20 Nov 2026. Its market capitalisation is ₹13,842 crore and it trades at 63.0 times earnings.

Share price
₹2,263.20 (20 Nov 2026)
Market cap
₹13,842 Cr (20 Nov 2026)
P/E
62.99 (20 Nov 2026)
Revenue
₹441 Cr (September 2026 quarter)
Net profit
₹60 Cr (September 2026 quarter)
ROCE
33.3% (FY26)
ROE
29.5% (FY26)
Book value
₹131 (FY26)
Dividend yield
0.44% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,719.30 / ₹1,336.60 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: CORONA

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.